Market revenue in 2023 | USD 716.5 million |
Market revenue in 2030 | USD 1,089.6 million |
Growth rate | 6.2% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 62.47% in 2023. Horizon Databook has segmented the Asia Pacific pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
In Asia Pacific, cancer has drawn more attention as a result of demographic shifts due to urbanization, a rapidly aging population, and economic expansion. A high prevalence of health risk factors, such as increasing alcohol & cigarette consumption, poor diet, obesity, and sedentary lifestyle, are contributing to the increasing prevalence of pancreatic cancer.
Various established players are expanding their presence in Asia Pacific, which is expected to boost the market. For instance, in June 2022, MGI collaborated with MiRXES to expand the region’s access to advanced spatial multiomics research capabilities.
This agreement was expected to expand the reach of the companies. Taiwan and Singapore governments offer favorable regulatory and funding support. However, low affordability, poor infrastructure, and lack of trained professionals are expected to restrain market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific pancreatic cancer diagnostic market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account